Regarding funding, almost 75% of industry-sponsored and other-sponsored trials excluded PWH explicitly (74.3% and 74.1%, respectively), and while this was a higher proportion than National Insitutes of Health–sponsored trials (57.1%), the difference did not reach statistical significance.
← all excerpts
Geospatial Access to CAR-T Clinical Trials for Non-Hodgkin Lymphoma for Persons With HIV.
1
—
—